Related Experiment Video
Updated: Sep 11, 2025
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Irritable bowel syndrome after Clostridioides difficile infection
Teodora Iacob1, Giuseppe Guido Maria Scarlata2, Ludovico Abenavoli2
1Hospital for Infectious Diseases, Cluj-Napoca, Romania.
Post-infectious irritable bowel syndrome (PI-IBS) developed in over half of patients following Clostridioides difficile infection (CDI). Severe CDI cases showed a higher risk of PI-IBS, necessitating proactive management to prevent long-term gastrointestinal issues.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Epidemiology
Background:
- Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder.
- Post-infectious IBS (PI-IBS) can develop after acute gastroenteritis, including Clostridioides difficile infection (CDI).
- Limited data exist on the risk and severity correlation of PI-IBS following CDI.
Purpose of the Study:
- To evaluate the risk of developing PI-IBS after a confirmed CDI.
- To investigate the correlation between CDI severity and PI-IBS onset.
Main Methods:
- A cross-sectional study involving 38 patients with confirmed CDI and 31 controls.
- CDI severity assessed by hospitalization, lab parameters, and symptoms.
- PI-IBS diagnosis at six months post-CDI using Rome IV criteria and Bristol Stool Scale.
Main Results:
- PI-IBS developed in 57% of the CDI group versus 25% in the control group (RR=2.29, p=0.04).
- A significant correlation was found between CDI severity and PI-IBS risk.
- 90% of hospitalized CDI patients developed PI-IBS (RR=2.72, p=0.0493).
Conclusions:
- Over half of patients experienced PI-IBS six months after CDI.
- Increased CDI severity correlates with a higher risk of PI-IBS.
- Proactive management of severe CDI is crucial to prevent long-term gastrointestinal complications.
More Related Videos
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
06:51Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:21Drugs for Treatment of Constipation-Predominant IBS